GI
CHRS icon

GAMMA Investing’s Coherus Oncology CHRS Stock Holding History

GAMMA Investing’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24K Sell
885
-325
-27% -$531 ﹤0.01% 3827
2026
Q1 		$2.04K Buy
1,210
+803
+197% +$1.43K ﹤0.01% 3660
2025
Q4 		$578 Buy
+407
New +$593 ﹤0.01% 3894
2024
Q4 		– Sell
-1,788
Closed -$1.86K – 3789
2024
Q3 		$1.86K Hold
1,788
– – ﹤0.01% 3094
2024
Q2 		$3.09K Hold
1,788
– – ﹤0.01% 2742
2024
Q1 		$4.27K Sell
1,788
-294
-14% -$723 ﹤0.01% 2471
2023
Q4 		$4.48K Buy
+2,082
New +$5.58K ﹤0.01% 2290

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

GAMMA Investing's CHRS Position: Q2 2026 in Review

GAMMA Investing reduced its Coherus Oncology (CHRS) stake by 27% in Q2 2026, selling an estimated $531 and leaving 885 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #3827.

GAMMA Investing first reported a position in CHRS in Q4 2023 and has held it in 7 quarters since. The position peaked at $4.48K in Q4 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • GAMMA Investing held 885 shares of Coherus Oncology worth $1.24K as of Q2 2026.
  • GAMMA Investing sold 325 Coherus Oncology shares in Q2 2026, an estimated $531.
  • Coherus Oncology made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3827 holding.
  • GAMMA Investing first reported a position in Coherus Oncology in Q4 2023 and has held it in 7 quarters since.
  • GAMMA Investing's Coherus Oncology position peaked at $4.48K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.